NPPB and type 2 diabetes mellitus: In the STEP‐HFpEF trial (n = 529, LVEF ≥45%, median BMI 37 kg/m2), semaglutide 2.4 mg once weekly led to greater reductions in body weight (−10.7%), improvements in KCCQ (+7.8 points), increased 6‐min walk distance (+20.3 m), and lower C‐reactive protein and NT‐proBNP levels compared to placebo at 52 weeks, in patients without type 2 diabetes mellitus (T2DM), regardless of baseline BMI, left ventricular ejection fraction (LVEF) and New York Heart Association (NYHA) class.11, 30